About: As of June 11, 2026, Adial Pharmaceuticals, Inc. was acquired by Azora Therapeutics, Inc. Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Glen Allen, Virginia.
Sector: Healthcare
Industry: Biotechnology
Latest price: $4.05 (-1.10%)
ADIL NASDAQ Adial Pharmaceuticals Inc
Adial Pharmaceuticals Inc share price
Atividade de preço de ADIL
Último preço
Variação (24h)
USD
Volume
-
Volume (média 4 sem.)
-
Fechamento anterior
N/D
Último negócio
ADIL price performance
ADIL details
quote.marketSignals